Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status

Authors

Allyson Hart, Hennepin Healthcare Research Institute
Yoon Son Ahn, Hennepin Healthcare Research Institute
Crystal Watson, Atara Biotherapeutics
Melissa Skeans, Hennepin Healthcare Research Institute
Arie Barlev, Atara Biotherapeutics
Bryn Thompson, Hennepin Healthcare Research Institute
Vikas R Dharnidharka, Washington University School of Medicine in St. Louis

Journal

Journal of Medical Economics

Publication Date

1-1-2021

Volume

24

Issue

1

First Page

620

Last Page

627

Document Type

Open Access Publication

DOI

10.1080/13696998.2021.1915793

Rights and Permissions

Hart A, Ahn YS, Watson C, Skeans M, Barlev A, Thompson B, Dharnidharka VR. Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status. J Med Econ. 2021 Jan-Dec;24(1):620-627. doi.org/10.1080/13696998.2021.1915793 © 2021 Atara Biotherapeutics. Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

Recommended Citation

Hart, Allyson; Ahn, Yoon Son; Watson, Crystal; Skeans, Melissa; Barlev, Arie; Thompson, Bryn; and Dharnidharka, Vikas R, "Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status." Journal of Medical Economics. 24, 1. 620 - 627. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11538